Medisprof S.R.L.

The Department of Medical Oncology at Medisprof S.R.L. conducts extensive research on Digestive System Diseases, focusing on cancers of the stomach, esophagus, pancreas, and colon, as well as neuroendocrine tumors. Trials seek to test new targeted agents and immunotherapy combinations to improve survival and quality of life for patients with advanced gastrointestinal malignancies.

• Advanced gastric and gastroesophageal junction adenocarcinoma
• Gastroenteropancreatic neuroendocrine tumors
• Chemotherapy‑induced thrombocytopenia in gastrointestinal cancers
• FGFR2b‑targeted therapy for HER2‑positive gastric cancer
• Combination immunotherapy for metastatic esophageal cancer

These studies aim to expand therapeutic options and provide faster access to innovative treatments for patients in Cluj Napoca and the wider region.

Research at Medisprof S.R.L. includes a strong focus on Female Urogenital Diseases, particularly ovarian and breast cancers that affect women of reproductive age. Clinical investigations evaluate novel hormonal and antibody‑based regimens to enhance response rates and reduce disease recurrence.

• High‑grade non‑mucinous epithelial ovarian cancer
• HER2‑positive metastatic breast cancer
• ER‑positive/HER2‑negative advanced breast cancer
• Combination therapies for ovarian cancer with PARP inhibitors
• Safety assessments of supportive care agents in women undergoing chemotherapy

The goal is to improve treatment effectiveness while preserving fertility and quality of life for female patients.

The oncology unit at Medisprof S.R.L. leads a broad portfolio of studies on Neoplasms, covering solid tumors such as melanoma, renal cell carcinoma, thyroid cancer, and various sarcomas. Trials are designed to evaluate the efficacy of checkpoint inhibitors, KRAS‑targeted drugs, and antibody‑drug conjugates in advanced disease settings.

• Advanced unresectable melanoma
• MET‑driven papillary renal cell carcinoma
• Medullary thyroid cancer with progressive disease
• KRAS G12C‑mutated non‑small cell lung cancer
• HER2‑positive gastric and gastro‑esophageal junction adenocarcinoma

By testing innovative therapeutic combinations, the site strives to extend overall survival and achieve durable disease control for patients with hard‑to‑treat cancers.

A major component of Medisprof S.R.L.’s clinical program addresses Respiratory Tract Diseases, especially various forms of lung cancer. Research evaluates new immunotherapy regimens, targeted inhibitors, and novel dosing strategies to improve response rates in both small‑cell and non‑small‑cell lung cancer.

• Advanced non‑small cell lung cancer (NSCLC) with EGFR exon 20 insertions
• PD‑L1‑positive metastatic NSCLC
• Limited‑stage small cell lung cancer after chemoradiotherapy
• KRAS‑mutated NSCLC receiving combination therapy
• Recurrent or metastatic head and neck squamous cell carcinoma with high PD‑L1 expression

These investigations aim to identify more effective, less toxic treatment options and to personalize therapy based on molecular biomarkers.

In addition to the primary specialties, Medisprof S.R.L. supports trials that span a range of unspecified therapeutic areas, including rare solid tumors and supportive care studies. The focus is on evaluating safety, tolerability, and patient‑centered outcomes across diverse disease contexts.

• Solid tumor basket studies with novel agents
• Supportive care for chemotherapy‑induced thrombocytopenia in breast cancer
• Pharmacokinetic similarity studies for biosimilar immunotherapies
• Combination regimens for metastatic triple‑negative breast cancer
• Evaluation of radiotherapy‑enhancing agents in head and neck cancer

These projects broaden the research portfolio, offering patients access to cutting‑edge therapies and contributing to the global understanding of cancer treatment.